Cost of revenue increased to $1,500,000 for the Q2 2024 compared to $700,000 in the same quarter for 2023, with the increase being primarily due to our sales force expansion during the Q4 2023. Research and development expenses were $9,400,000 in the Q2 of 2024 compared with $17,700,000 in 2Q2023, which included a $10,000,000 upfront license fee to Pharmosa for the exclusive license to L-six zero six in North America. We saw a $1,400,000 decrease in expenses related to our Eutrepia program driven by expensing pre launch inventory costs in the prior year. These decreases were offset by a $1,700,000 increase in clinical expenses related to our L-six zero six program and a $1,500,000 increase in personnel expenses related to increased headcount. General and administrative The increase of $10,800,000 was primarily due to a 6,300,000 The increase of $10,800,000 was primarily due to a $6,300,000 increase in personnel expenses, which includes stock based compensation, a $2,200,000 increase in commercial and consulting expenses and a $900,000 increase in legal fees related to our ongoing utrepia related litigation.